http://rdf.ncbi.nlm.nih.gov/pubchem/reference/13960276

Outgoing Links

Predicate Object
contentType Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage iv, ix
issn 1366-5278
2046-4924
issueIdentifier 17
pageRange iii-iv, ix
publicationName Health technology assessment (Winchester, England)
startingPage iii
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5d10530eeb9c2e5699014abbfff60e1
bibliographicCitation Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006 May;10(17):iii–iv, ix. doi: 10.3310/hta10170. PMID: 16707074.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a52cb7983d1739ff43018306f11db49c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53ba2a8c824b8bb06b2419f6ed4626e5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ee1f634a39ff81da8ca1abc005578ad
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e68f84afc2b60243729d418a57b0d50
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b81a93873c681326e4d445731a5ce2f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86e30cd5477f283b45144910ce35c4c0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b3c59523fc7c5ae0e89cbb3bdf3ea28f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ed51509b6cd148e240babd0d1fb23fe0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d20b552ab1fbeced6752322765a62e92
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7e8b5bcc8e488be5f65be72049ab1b8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52c8775eaf35a25e144784f0d3fa743d
date 200605
identifier https://pubmed.ncbi.nlm.nih.gov/16707074
https://doi.org/10.3310/hta10170
isPartOf https://portal.issn.org/resource/ISSN/2046-4924
https://portal.issn.org/resource/ISSN/1366-5278
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/20788
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
discusses http://id.nlm.nih.gov/mesh/M0021770
http://id.nlm.nih.gov/mesh/M0004649
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D014150Q000627
http://id.nlm.nih.gov/mesh/D003024Q000627
http://id.nlm.nih.gov/mesh/D012559Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000293
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D014150Q000009
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D014150Q000191
http://id.nlm.nih.gov/mesh/D017060
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D011788
http://id.nlm.nih.gov/mesh/D038801
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D003024Q000009
http://id.nlm.nih.gov/mesh/D012559Q000145
http://id.nlm.nih.gov/mesh/D012559Q000191
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7025
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5002
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398737
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2159
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398745
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5073
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135409468

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129101897
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129409886
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128442098
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129098622
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128751968

Total number of triples: 65.